Coherus BioSciences, Inc. announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N. Newcomer, M.D., to its Board of Directors effective February 2, 2022. Dr. Newcomer spent the majority of his career with UnitedHealthcare, where he most recently served as Senior Vice President, Oncology and Genetics, focusing on improving the affordability and quality of oncology care. He joined UnitedHealthcare in 1991 as Chief Medical Officer.

Earlier, Dr. Newcomer served as Medical Director for CIGNA Health Care of Kansas City and was a practicing oncologist for nine years. Dr. Newcomer serves on the boards of directors of Cellworks Group and Myriad Genetics. Coherus also announced James Healy, M.D., Ph.D., a board member since 2014, has resigned from the Coherus Board of Directors.

Coherus expects to retain Dr. Healy as a consultant to help with the Company's immuno-oncology strategy. Dr. Newcomer was appointed as a Class I director, with a term of office expiring at the Company's 2024 annual meeting of stockholders and as a member of the Compensation Committee, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. On February 2, 2022, Mark D. Stolper tendered his resignation to the Board as a Class III director subject to his immediate reappointment as a Class II director.

On February 2, 2022, the Board accepted Mr. Stolper's resignation and immediately reappointed him as a Class II director.